On 30 October 2026 the U.S. Food and Drug Administration granted accelerated approval to Voceryq, a plasmid DNA immunotherapy, for adults with recurrent respiratory papillomatosis. The agency's announcement says it is the first plasmid DNA-based immunotherapy approved in the United States. The approved indication is specific: Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) is indicated to reduce how often adults with the disease need surgery to remove papillomas. Approval continues only if later studies verify clinical benefit.

Recurrent respiratory papillomatosis is a rare, chronic disease caused by human papillomavirus types 6 and 11. Wart-like growths form in the airways, most often on the vocal cords, and can cause hoarseness, a chronic cough, voice changes, and, in severe cases, difficulty breathing. Surgery can remove the growths. The FDA says there is no cure, the virus can remain in the tissue, and patients often need repeated procedures over many years. In some cases the disease becomes cancerous.

Voceryq is two DNA plasmids given by intramuscular injection with the CELLECTRA 5PSP device. The plasmids are designed to make cells produce HPV-6 and HPV-11 antigens, plus interleukin-12, a signal meant to strengthen the immune response. Electroporation, a brief electrical pulse from the device, opens temporary pores in cell membranes so the plasmids can enter. The label dose is 1 mL, containing 6.25 mg, every three weeks for four doses, given only by a clinician trained on that device. Before the first dose, visible papilloma is surgically removed so treatment starts with as little residual growth as possible. The FDA had already granted Breakthrough Therapy and Orphan Drug designations.

The approval letter licenses Inovio Pharmaceuticals to manufacture the product. Drug-product manufacturing is approved at Alliance Medical Products, which trades as Siegfried, in Irvine, California. Inovio said it expects doses to be available to order in about 60 days, with a fuller launch in the first quarter of 2027.

The study behind the approval

The evidence is study RRP-001, registered as NCT04398433. The prescribing information describes it as an open-label, single-arm study in adults. The FDA announcement also describes it as multicenter. It enrolled 32 adults with clinically and histologically confirmed disease who had needed at least two surgeries for laryngotracheal papillomas in the previous 12 months. Everyone had a standard operation just before treatment, on day 0, then injections on day 0 and at weeks 3, 6, and 9. All 32 received 6.25 mg at each visit. Median age was 46.5 years (range 25 to 82), and 24 patients (75%) were male.

Efficacy was judged in a subset. Twenty-six of the 32 had required three or more surgeries in the 12 months before treatment. In that group the median number of excisions was 4.5, ranging from 3 to 8, and the surgery just before the first dose is included in that count. The protocol did not require any further papilloma surgery during the nine-week dosing window. The endpoint was a complete response: no surgical intervention in the 12 months after treatment.

Seven of those 26 patients met it. That is 27%, with a 95% confidence interval of 12% to 48%. The other 19 in the group of 26 did not. The label states that a year without surgery is not the expected course of untreated disease. The study had no concurrent untreated comparison group. The approval letter says this accelerated approval rests on surgery frequency as an intermediate endpoint reasonably likely to predict benefit. Clinical benefit still has to be verified, including a lasting end to excisions and improvement in symptoms.

Safety, and the study still required

Among the 32 patients, the most common adverse reactions were injection-site reactions in 11 patients (34%), headache in 6 (19%), fatigue in 5 (16%), hypertension in 4 (13%), nausea in 2 (6%), and dizziness in 2 (6%). The label also lists less frequent events, including cholecystitis in one patient (3%). Electroporation can cause brief muscle contractions, temporary bleeding, anxiety, fainting reactions, a short-lived change in creatine phosphokinase, redness, and pain. The label says to avoid treating the same arm as a pacemaker or implanted defibrillator, and to avoid skin that is irritated, scarred, bruised, or tattooed, or that has a metal implant. Patients are to be watched for at least 30 minutes after an injection. The label has no human pregnancy or lactation data. Safety and effectiveness are not established in children. Too few participants were 65 or older to show whether age changes the response.

The approval letter requires another adequate and well-controlled study. It should enroll at least 50 adult and pediatric patients who needed three or more surgeries in the prior year, follow the need for surgery for at least three years after treatment, and compare results with an external control group or a scientifically justified threshold. A draft protocol is due by 30 December 2026 and a final protocol by 30 June 2027. Completion is scheduled for 30 December 2031, with the final report due by 30 August 2032. If the study does not verify benefit, or is not carried out with due diligence, the FDA may withdraw the approval. The efficacy group is small, the confidence interval is wide, and the trial had no concurrent control arm.